The global cord blood banking industry has been rapidly-changing over recent years, due to changes in processing, storage, and transplantation technologies. These changes require you to have a firm understanding of emerging trends and how they would impact your business model. Furthermore, research advances do not know international boundaries, so they are shared nearly instantly from region-to-region.
Importantly, a trend toward diversification has been emerging within the cord blood banking industry, with cord blood banks effectively becoming diversified stem cell biobanks.
Cord blood banks worldwide has started to incorporate the storage of umbilical cord tissue, placental tissue, amniotic fluid, menstrual fluid, and more.
They are also starting to store other stem cell tissues sources, such as teeth, adipose tissue , bone marrow, peripheral blood, and more.
Cord blood banking is a specialized niche, so there are several key benefits to diversifying into related areas of stem cell storage, including increased revenue potential and diversification, with minimal risk and up-front investment.
Partnership with American Cryostem, Adipose-Derived Stem Cell Expert
For this reason, BioInformant partnered with American Cryostem, an American-based company that offers cord blood banks the opportunity to license their adipose tissue and adipose-derived stem cell processing and storage platform technologies, as well as marketing materials, to allow for fast integration of these services.
American Cryostem will grant only one exclusive license per region, so this may limit your ability to partner with them for adipose tissue and stem cell collection, processing, storage, expansion and differentiation services.
However, if a license is available for your region, this could be one of the fastest and most efficient ways to incorporate adipose-tissue storage into your cord blood banking model.
Once you evaluate this benefits of this opportunity to your company, you can contact BioInformant at [email protected] to request an:
- Overview of the key benefits that American Cryostem offers to licensees
- Introduction letter from the company American Cryostem
To learn more about emerging opportunities within the cord blood banking market, view the “Complete 2015-16 Global Cord Blood Banking Industry Report.”
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.